Terrie Curran, Phathom Pharmaceuticals CEO (Arcutis)

Phath­om Phar­ma­ceu­ti­cals re­sub­mits NDA for acid block­er, bags $130M+ from of­fer­ing

Phath­om Phar­ma­ceu­ti­cals is mak­ing an­oth­er run at get­ting a green light to add two new in­di­ca­tions for its drug vono­prazan while pric­ing a pub­lic of­fer­ing to bring in $130.7 mil­lion, the com­pa­ny an­nounced to­day.

In Feb­ru­ary, the FDA sent the com­pa­ny com­plete re­sponse let­ters for its ero­sive esophagi­tis NDA and H. py­lori post-ap­proval sup­ple­ment to “ad­dress spec­i­fi­ca­tions and con­trols for a ni­trosamine drug sub­stance re­lat­ed im­pu­ri­ty, N-ni­troso-vono­prazan.”

Endpoints News

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters